LIQUENT ANNOUNCES SUPPORT FOR MICROSOFT'S DIGITAL PHARMA INITIATIVE
Liquent Solutions Enable Life Sciences Companies to Meet FDA Submission Deadlines
Philadelphia, Pennsylvania, USA - August 15, 2005 — Thomson Scientific today announced Liquent's support of Microsoft's Digital Pharma initiative, a vision and solutions framework that addresses the industry imperatives of speed-to-insight and value-for-cost, by helping improve productivity, integrate disparate data sources, and enable better collaboration across the pharmaceutical value chain.
Thomson's Liquent regulatory solutions business provides software and services that help ensure that Life Sciences companies can meet the strict standards of regulatory authorities across the world by helping them achieve quality, accuracy and data integrity in order to deliver regulatory reports and submissions reliably and on time. Liquent recently announced its new Structured Product Labelling (SPL) conversion service which has been developed in response to new FDA guidelines that state that drug manufacturers need to submit their prescription product labelling electronically in the SPL format. To help life sciences companies overcome the challenges that the new guidelines present, Liquent's team of Regulatory Affairs experts use a Microsoft technology-based solution to quickly convert labels to SPL format.
A unique feature of the Liquent service is that only the trained and experienced Regulatory Affairs professionals are used to review the content and conversion through every step. In order to ensure, accuracy, quality and compliance, the QC process is performed by two different trained Liquent Regulatory Affairs professionals and the skills and experience of these professionals add unrivalled value from both technical and business compliance perspectives.
"The new FDA SPL format guidelines have presented life sciences companies a major challenge - to convert potentially large volumes of labels while responding to mission critical timelines that are key to product launch," commented Jim Nichols , Liquent's Vice President of Product Strategy and Marketing. "We are seeing a steady increase in the volume of labels that we are converting and we are delighted to align with Microsoft's Digital Pharma initiative to deliver complementary technologies and help our clients achieve speed- to-insight, a key imperative of the Digital Pharma framework."
Microsoft Digital Pharma launch partners include Accenture, Datalabs, HP, Manhattan Associates, Siebel Systems and other 12 life sciences solution providers. The solutions provided by this strong partner network address key industry issues across the life sciences value chain, from drug development, data collection, business intelligence to sales and marketing effectiveness. Aligned with Microsoft's Digital Pharma vision and based on open industry standards, these solutions are built on proven platforms, using Microsoft's .NET Framework, the programming model for building Extensible Markup Language (XML)-based Web services and applications.
"Faced with a rapidly changing regulatory environment, life sciences companies need innovative solutions that reduce complexity and enable organizations to stay ahead of their competitors," said Steve Shihadeh , general manager, Microsoft Healthcare and Life Sciences. "We are pleased to align with knowledgeable, experienced partners like Liquent, whose SPL solution exemplifies the vision embraced by Microsoft's Digital Pharma initiative."
About Microsoft's Digital Pharma
Microsoft's Digital Pharma provides a practical vision and framework that enables pharmaceutical companies to drive innovation across the enterprise and address strategic value-chain capability requirements. Using proven Microsoft technology, Digital Pharma illustrates how drug manufacturers can achieve speed-to-insight and value-for-cost: two distinct industry imperatives that lead the way for business transformation. More information can be found at www.microsoft.com/lifesciences
About Liquent regulatory solutions
Liquent regulatory solutions provides software, information products, and related services for the life sciences industry. These solutions and services help ensure clients meet the strict standards of regulatory authorities across the world helping them achieve quality, accuracy, and data integrity to deliver regulatory reports and submissions reliably and on time.
As a result, 48 of the top 50 global life sciences companies rely on Liquent regulatory solutions to stay current with the latest intelligence and to provide the technology and services to compress the regulatory submissions and approval process, improving speed to market, cost control, and productivity, all of which contribute to ensuring patients' and physicians' timely access to new drugs. Over the last decade, more than 5,000 regulatory submissions have been produced using Liquent world-class products and expert services. For more information please visit, www.liquent.com.
Thomson Reuters (www.thomsonreuters.com), with 2005 revenues of approximately $8.5 billion, is a global leader in providing integrated information solutions to business and professional customers. Thomson provides value-added information, software tools and applications to more than 20 million users in the fields of law, tax, accounting, financial services, higher education, reference information, corporate e-learning and assessment, scientific research and healthcare. With operational headquarters in Stamford, Conn., Thomson has approximately 40,500 employees and provides services in approximately 130 countries. The Corporation’s common shares are listed on the New York and Toronto stock exchanges (NYSE: TOC; TSX: TOC).
Scientific is a business of Thomson Reuters. Its information solutions assist professionals at every stage of research and development—from discovery to analysis to product development and distribution. Thomson scientific information solutions can be found at www.scientific.thomson.com.
Media Contact
